{
    "clinical_study": {
        "@rank": "10151", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: This phase II trial is studying temozolomide to see how well it works in treating\n      patients with mycosis fungoides or Sezary syndrome that has not responded to previous\n      treatment."
        }, 
        "brief_title": "Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome", 
        "completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Mycoses", 
                "Mycosis Fungoides", 
                "Sezary Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate to temozolomide in patients with relapsed mycosis fungoides\n           or Sezary syndrome.\n\n        -  Determine the toxic effects of this drug in these patients.\n\n        -  Correlate pretreatment AGT activity in tumor cells with response to this drug in these\n           patients.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in\n      the absence of disease progression or unacceptable toxicity for a maximum of 1 year.\n\n      Patients are followed every 3 months.\n\n      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed mycosis fungoides or Sezary syndrome\n\n               -  Stage IB-IVB disease\n\n               -  Must have failed at least one prior systemic therapy\n\n               -  Generalized erythroderma allowed\n\n          -  Measurable disease and at least one indicator lesion OR evaluable disease for\n             erythrodermic patients only\n\n               -  Prior radiotherapy to areas of measurable disease allowed if disease progression\n                  is present in the site or if measurable disease is present outside irradiation\n                  port\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  At least 3 months\n\n        Hematopoietic:\n\n          -  WBC at least 3,000/mm^3\n\n          -  Absolute granulocyte count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 2.2 mg/dL\n\n          -  SGOT or SGPT no greater than 2 times upper limit of normal (ULN)\n\n          -  Alkaline phosphatase no greater than 2 times ULN\n\n        Renal:\n\n          -  Creatinine no greater than 2.0 mg/dL\n\n        Cardiovascular:\n\n          -  No New York Heart Association class III or IV heart disease\n\n          -  No clinically significant peripheral venous insufficiency\n\n        Other:\n\n          -  HIV negative\n\n          -  No poorly controlled diabetes mellitus\n\n          -  No acute infection requiring IV antibiotics\n\n          -  No other medical condition that would prevent ingestion or absorption of oral\n             medication\n\n          -  No other neoplasm within the past 5 years except curatively treated squamous cell or\n             basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  At least 4 weeks since prior biologic therapy and recovered\n\n          -  No concurrent growth factors or epoetin alfa\n\n        Chemotherapy:\n\n          -  At least 4 weeks since prior chemotherapy and recovered\n\n        Endocrine therapy:\n\n          -  At least 4 weeks since prior topical steroids\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 2 weeks since prior radiotherapy for local control or palliation and\n             recovered\n\n        Surgery:\n\n          -  Recovered from prior major surgery\n\n        Other:\n\n          -  No other concurrent investigational drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004106", 
            "org_study_id": "NU FDA97H3", 
            "secondary_id": [
                "NU-FDA97H3", 
                "NCI-G99-1597", 
                "STU00010001"
            ]
        }, 
        "intervention": {
            "description": "Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks", 
            "intervention_name": "temozolomide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Temozolomide", 
                "Dacarbazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage I cutaneous T-cell non-Hodgkin lymphoma", 
            "stage II cutaneous T-cell non-Hodgkin lymphoma", 
            "stage III cutaneous T-cell non-Hodgkin lymphoma", 
            "stage IV cutaneous T-cell non-Hodgkin lymphoma", 
            "recurrent cutaneous T-cell non-Hodgkin lymphoma", 
            "stage I mycosis fungoides/Sezary syndrome", 
            "stage II mycosis fungoides/Sezary syndrome", 
            "stage III mycosis fungoides/Sezary syndrome", 
            "stage IV mycosis fungoides/Sezary syndrome", 
            "recurrent mycosis fungoides/Sezary syndrome"
        ], 
        "lastchanged_date": "May 31, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06520-8028"
                    }, 
                    "name": "Yale Comprehensive Cancer Center at Yale University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611-3013"
                    }, 
                    "name": "Robert H. Lurie Comprehensive Cancer Center at Northwestern University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637-1470"
                    }, 
                    "name": "University of Chicago Cancer Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of Temozolomide for the Treatment of Mycosis Fungoides and the Sezary Syndrome", 
        "overall_official": {
            "affiliation": "Robert H. Lurie Cancer Center", 
            "last_name": "Timothy M. Kuzel, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Disease response will be assessed using bi-dimensional measurements of lesions with clearly defined margins by medical photograph (skin lesion) or by radiological imaging (internal lesions).", 
            "measure": "Response rate", 
            "safety_issue": "No", 
            "time_frame": "After every 2 cycles of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004106"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Northwestern University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Northwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2012", 
        "why_stopped": "Per Data Monitoring Committee given the poor/inadequate accrual."
    }, 
    "geocoordinates": {
        "Robert H. Lurie Comprehensive Cancer Center at Northwestern University": "41.878 -87.63", 
        "University of Chicago Cancer Research Center": "41.878 -87.63", 
        "Yale Comprehensive Cancer Center at Yale University School of Medicine": "41.308 -72.928"
    }
}